Page last updated: 2024-11-02

pentoxifylline and ST Elevated Myocardial Infarction

pentoxifylline has been researched along with ST Elevated Myocardial Infarction in 1 studies

Research Excerpts

ExcerptRelevanceReference
"Pentoxifylline is a methylxanthine derivative with known anti-inflammatory, antioxidant, vasodilator, and rheological properties which can be a promising agent in preventing reperfusion injury."7.30Evaluating the role of intravenous pentoxifylline administration on primary percutaneous coronary intervention success rate in patients with ST-elevation myocardial infarction (PENTOS-PCI). ( Aghakouchakzadeh, M; Amoli, AI; Hosseini, SH; Jalali, A; Jenab, Y; Kakavand, H; Naderian, M; Pourhosseini, H; Saadatagah, S; Sadri, F; Salarifar, M; Talasaz, AH, 2023)
"Pentoxifylline is a methylxanthine derivative with known anti-inflammatory, antioxidant, vasodilator, and rheological properties which can be a promising agent in preventing reperfusion injury."3.30Evaluating the role of intravenous pentoxifylline administration on primary percutaneous coronary intervention success rate in patients with ST-elevation myocardial infarction (PENTOS-PCI). ( Aghakouchakzadeh, M; Amoli, AI; Hosseini, SH; Jalali, A; Jenab, Y; Kakavand, H; Naderian, M; Pourhosseini, H; Saadatagah, S; Sadri, F; Salarifar, M; Talasaz, AH, 2023)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Kakavand, H1
Saadatagah, S1
Naderian, M1
Aghakouchakzadeh, M1
Jalali, A1
Sadri, F1
Amoli, AI1
Hosseini, SH1
Jenab, Y1
Pourhosseini, H1
Salarifar, M1
Talasaz, AH1

Trials

1 trial available for pentoxifylline and ST Elevated Myocardial Infarction

ArticleYear
Evaluating the role of intravenous pentoxifylline administration on primary percutaneous coronary intervention success rate in patients with ST-elevation myocardial infarction (PENTOS-PCI).
    Naunyn-Schmiedeberg's archives of pharmacology, 2023, Volume: 396, Issue:3

    Topics: Administration, Intravenous; Antioxidants; Humans; Infusions, Intravenous; Myocardial Infarction; Pe

2023